Diabetes and Pancreatic Cancer
There is great emphasis on early identification of high risk patients for developing pancreatic cancer in an attempt to reduce the burden of the fourth leading cause of cancer death in the United States. Abstracts presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted and supported the relationship between pancreatic cancer and diabetes mellitus and Abstract #4039 showed that hemoglobin-A1c at the time of diagnosis correlates with disease stage and predicts survival among all stages of pancreatic cancer patients. Abstracts #4044 and #e15110 also presented in 2013 ASCO Annual Meeting showed that metformin treatment serves as a positive prognosticator, especially in patients with diabetes mellitus diagnosed within 2 years of pancreatic cancer and in stage 3 pancreatic cancer patients with diabetes mellitus.
Image: Metformin activates AMPKThr172 through the LKB1 signalling pathway.
Siegel R, Naishadham D, Jemal A, et al. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773–783
DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999;117:1464–1484
Matsubara S, Tada M, Akahane M, et al. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. Pancreas. 2012;41:1241–1246
Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. J Am Med Assoc.1995;273:1605–1609
Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. J Am Med Assoc. 2005;293:194–202
Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159(2):101-7
Gullo L, Pezzilli R, Morselli-Labate AM et al. Diabetes and the risk of pancreatic cancer.N Engl J Med 1994; 331(2):81-4
Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101
Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134:981–987
Pannala R, Leibson CL, Rabe KG, et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol. 2009;104:2318–2325
Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88–95
Gullo L, Pezzilli R, Morselli-Labate AM. Italian Pancreatic Cancer Study Group: Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 331:81-4.
Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007; 96(3):507-509
Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. European Journal of Cancer. March 2011; 1-7.
Huxley R, Ansary-Moghaddam A, Berrington de González A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92(11):2076-2083.
Chiu CC, Huang CC, Chen YC, et al. Increased Risk of Gastrointestinal Malignancy in Patients with Diabetes Mellitus and Correlations with Anti-Diabetes Drugs: A Nationwide Population-based Study in Taiwan. Intern Med 2013; 52(9):939-46
Mizuno S, Nakai Y, Isayama H et al. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology2013; 13(3): 285-289
Singh S, Singh PP, Singh AG et al. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol. 2013 Apr;108(4):510-9
Zhang P, Li H, Tan X et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiology. June 2013;37(3):207-18.
Fan K, Dholakia AS, Wild AT, et al. Hemoglobin-A1c level to predict for clinical outcomes in patients with pancreatic cancer. J Clin Oncol 31, 2013 (suppl; abstr #4039)
Esbah O, Oksuzoglu B, Erenet T, et al. Metformin in diabetic pancreatic cancer patients: Benefit or not—Multicenter experience. J Clin Oncol 31, 2013 (suppl; abstr #e15110)
Oh DY, Choi Y, Kim TY, et al. The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy. J Clin Oncol 31, 2013 (suppl; abstr #4044)
Caporicci D, Mori A, Pepi R et al. Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus. La Clinica Therapeutica 1979;88(4):372-86
Cusi K, Consoli A, DeFrinzo RA et al. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism 1996;81(11):4059-67
Karnevi E, Said K, Andersson R et al. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013, 13:235
Copyright (c) 2014 Najla Hatem El-Jurdi, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.